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S352 Poster Session IIALL with leukocytes .30/nl at diagnosis and/or delayed CR (.4
weeks), pro B-ALL or complex karyotype, T lineage ALL (prae T-
ALL, mature T-ALL) and standard risk ALL (SR-ALL) with molec-
ular persistence or relapse are candidates for SCT in CR1. Pts with
siblings have a 25% probability (prob) of an HLA identical sibling.
Pts without an HLA identical sibling have a chance of 80% to find
a compatible unrelated donor.
Here, we report our single centre data on SCT from sibling and
unrelated donors. High resolution HLA typing class I+II was done
since 01/2006. Between 2006 and 2010, 36 pts with ALL, CR1 un-
derwent SCT. 12 pts had a sibling donor, 14 pts an HLA identical
unrelated donor (MUD) and 10 pts an HLA compatible unrelated
donor (MMUD). All HLA mismatches were in class I, 9/10 pairs
had 1 mismatch (HLA-C antigen 4, HLA-A antigen 3, HLA-B allele
2) and 1/10 pairs had 2 mismatches (HLA-C antigen and HLA-B al-
lele). Median age was 43 (18-67) years (yrs), not different between
sibling or unrelated SCT. Indication for SCT: 14/36 pts belonged
to the VHR group, 19/36 pts to the HR group and 3/36 pts of the
SR group had molecular relapse. All pts were transplanted in CR1
(bone marrow \5% blasts). Conditioning was myeloablative
(MAC) in 30/36 pts (12 Gy TBI and VP 16 or CY 29, other 1) and
in 6/36 pts reduced intensity (RIC). Pts with unrelated donors re-
ceived antithymocyte globuline (ATG) (60mg/kg in MAC, 40mg/
kg in RIC).
Results: 25/36 pts are alive in CR (median f/u 40 months, 7-66), 11/
36 pts died 8 months (0.5-24) after SCT. Causes of death: leukemia
3, infection6GvHD 6, other 2. Prob of OS for all pts (36) at 4 yrs is
0.65, 0.82 for SCT with sibling donors, 0.52 for MUD-SCT, 0.56
for MMUD-SCT. The differences were not significant. Prob of
LFS is 0.59 for all pts, in pts with sibling donors 0.82, after MUD-
SCT 0.49 and 0.44 after MMUD-SCT. Prob of NRM for all pts
was 0.26, in sibling SCT 0.18, in MUD-SCT 0.34 and in
MMUD-SCT 0.26.
Conclusion: In ALL, CR1 SCT afterMAC and with a sibling donor
is still the gold standard (OS 0.82). In unrelated donor SCTwe found
no difference in survival between HLA identical or 1 antigen mis-
matched donor-recipient pairs. It has to be discussed if dose reduc-
tion of ATG in MUD-SCT might improve the results by
decreasing NRM and relapse post SCT.400
NONABLATIVE CONDITIONING REGIMEN FOR CD20+ B-CELL LYM-
PHOID MALIGNANCIES: SHOULD CONDITIONING REGIMENS BE INDI-
VIDUALIZED TO OPTIMIZE TRANSPLANT OUTCOME?
Chinratanalab, W.1,2, Reddy, N.1, Greer, J.P.1, Engelhardt, B.1,
Kassim, A.1, Morgan, D.1, Brandt, S.J.1,2, Jagasia, M.1,
Goodman, S.1,2, Savani, B.N.1,2 1Vanderbilt University Medical Center,
Nashville, TN; 2Tennessee Valley Healthcare System, Nashville, TN
Background:Allogeneic stem cell transplantation (allo-SCT) is lim-
ited by transplant-related-mortality (TRM), primarily mediated by
graft-versus-host disease (GVHD). Disease specific preparative reg-
imens that offer acceptable graft-versus-host disease (GVHD)-asso-
ciated morbidity and TRM are preferred. The B-cell lymphoma
specific nonablative (NST) regimen fludarabine, cyclophosphamide
and rituximab (FCR) is reportedly safe and effective, however most
reported data are from single institution.
Methods: Twenty six pts with recurrent CD20+ B-cell lymphoid
malignancies received FCR NST allo-SCT between March 2008
and May 2011. The conditioning regimen consisted of fludarabine
(30 mg/m2 daily for 4 days), cyclophosphamide (750 mg/m2 daily
for 3 days) and rituximab (375 mg/m2, day-13,-6,+1,+8). This was
followed by either related (n 5 18) or unrelated donors (n 5 8)
allo-SCT. All patients received tacrolimus and mini-methotrexate
GVHD prophylaxis (rATG for unrelated donor allo-SCT).
Results: The median age of pts at transplantation was 59 years
(range 41-64). Ten pts had CLL, 7 MCL, 3 DLBCL, 3 FL and 3
transformed-lymphoma. At diagnosis, 20 (77%) pts had stage IV dis-
ease. Twenty three pts (88%) received $3, 14 (54%) $4 regimens
and 4 (15%) had prior autologous-SCT. Nine (35%) pts were in
complete remission pre-SCT following salvage therapy. At the
time of analysis, 17 pts were alive with an estimated 2-year OS and
PFS of 63%, and non-relapse mortality (NRM) 25%. Grade II-IV
aGVHD occurred in 8 (31%) pts and chronic GVHD in 6 (24%)pts (extensive 5 3). Causes of death includes progressive disease 4,
aGVHD2 (both after receivingDLI formixed chimerismwith resid-
ual disease), infection 1 and others 2 (substance abuse, leucoence-
phalopathy). Only 6 pts required re-hospitalization within 100
days of SCT, (average 10 days; range, 3-18).
Conclusion: Our data suggests nonablative FCR conditioning reg-
imen is safe and effective in heavily pre-treated B-cell lymphoid ma-
lignancies. While our conclusion is limited by the small sample size,
this suggests the need for larger prospective studies to validate the ef-
ficacy of FCR and to compare it with other reduced-intensity condi-
tioning allo-SCT in B-cell malignancies. We recommend that FCR
allo-SCT be considered early and novel strategies (radioimmuno-
therapy, tandem auto-allo-SCT) be incorporated and evaluated to
major cause of failure, particularly in heavily pre-treated pts.401
EBV-POSITIVE LYMPHOPLASMACYTIC LYMPHOMA: A HIGHLY AGGRES-
SIVE POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH
MULTIORGAN INVOLVEMENT
El Amil, Z.G.1, Tuncer, H.H.1,2, Al-Malki, M.M.1, L’Heureux, J.1,
Welch, P.1, Roy, T.S.1, Al-Homsi, A.S.1,2 1Roger Williams Medical Cen-
ter, Providence, RI; 2Boston University School of Medicine, Boston, MA
Post transplant lymphoproliferative disorder (PTLD) is a hetero-
geneous disease ranging from benign polyclonal proliferation of B
cells to monoclonal B cell proliferation. Its cumulative incidence is
about 1% with most cases observed during the first year. Most cases
are associated with Epstein-Barr virus (EBV) infection. Indolent
lymphomas are not considered part of PTLD in the WHO 2008
classification.
Here we describe two cases of EBV related post transplant lym-
phoplasmacytic lymphoma (LPL) with multiorgan failure and ag-
gressive course. The first patient was an EBV positive 28-year old
male with refractory Hodgkin’s lymphoma following autologous
transplant. The second was an EBV negative 57-year old male
with relapsed peripheral T-cell lymphoma, otherwise non-specified.
They underwentmatched unrelated allogeneic transplant after being
conditioned with fludarabine, busulfan and ATG. They received
methotrexate and cyclosporine for GVHD prophylaxis. On Day
+20 post transplant, the first patient presented with fever, nausea, di-
arrhea, and bilateral cervical lymphadenopathy. He had pancytope-
nia, elevated liver enzymes, and acute renal failure. Bone marrow
aspirate and biopsy findings were consistent with monomorphic
LPL with normal cytogenetics. Biopsies of a cervical lymph node,
duodenum and a colonic mass revealed the same histology. Serum
protein immunofixation (SPIF) showed biclonal IgG kappa and
lambda, IgA kappa and biclonal IgM lambda gammopathy. EBV
PCRwas 0.597x106 copies/ml.Hewas treated with immunosuppres-
sion tapering, cyclophosphamide and rituximab with no evidence of
improvement. The second patient presented with fever on day +35
post transplant. He had cervical, retroperitoneal and inguinal lymph-
adenopathy, splenomegaly, as well as pancytopenia, elevated liver
enzymes and acute renal failure. Bonemarrow aspirate and biopsy re-
vealed a monomorphic LPL. SPIF showed biclonal IgG kappa para-
protein with lambda chains. EBV PCR was 1.38x106 copies/ml. He
was treated with immunosuppression tapering and rituximab but his
condition deteriorated rapidly.
We described two cases of EBV driven post transplant LPL with
profound protein abnormalities and multiorgan failure despite indo-
lent morphology. Although indolent lymphomas are not considered
part of PTLD, clinicians must be aware of this presentation. Severity
of cases and lackof response to treatment should further bring intodis-
cussion the role of EBV load regular monitoring in patients at risk.402
SENSITIVE REAL-TIME PCR CHIMERISM ASSAY FOR HSCT MONITORING
Smith, M.S., Cowden, S.M., Kleiboeker, S.B. Viracor-IBT Laboratories,
Lee’s Summit, MO
Chimerism testing, or themeasurement of the percent of recipient
and donor hematopoietic cell origin, is a standard of care for HSCT
recipients. For leukemic recipients, the quantification of chimerism
Table 1. Patient and Product Characteristics
Transplant Variable
Ethnically
Matched
Ethnically
Mismatched
Ethnic Group
Recipient Donor
Caucasian Caucasian 97.1%
Poster Session II S353can aid in the early detection of relapsing leukemia, especially when
leukemia-specific mutation assays are not available. Detection of in-
creasing recipient-origin (mixed) chimerism may be useful in deci-
sions to alter immunosuppression, to administer donor lymphocyte
infusions, or for other treatment changes.
Previous reports showed complete chimerism correlated well with
overall survival and negatively with relapse probability. In the U.S.,
detection of chimerism is performed using PCR for variable number
or short tandem repeats, followed by fragment separation by capil-
lary electrophoresis, resulting in poor sensitivity below 10% recipi-
ent DNA due to the imprecision of measurements of areas under the
peaks in fragment separation, as well as problematic stutter artifacts.
The higher sensitivity of detection of chimerism provided by the
real-time PCR assay could be beneficial in allowing for earlier detec-
tion of increasingmixed chimerismwith the proviso that the assay be
performed at an optimal frequency for the underlying type of
leukemia.
Previous real-time PCR assays for chimerism were not able to de-
tect an informative marker for the ‘‘recipient’’ in all ‘‘donor/recipi-
ent’’ pairs due to insufficient numbers of markers. Our assay of 28
marker loci detected at least one informative marker (IM) in 754 of
756 directional combinations of DNAs (99.7%), with an average of
5.1 markers per pair. In a subset of 28 first-degree relative pairs,
one or more IMs were found in 27 pairs (96.4%), with an average
of 3.5 IM/pair. Linearity of markers was examined by dilution of
DNA from an IM+ donor in IM-DNA. All markers showed linearity
with good PCR efficiency values. A single copy gene was used for
normalizing the % chimerism with a DDCt method using simulated
post-transplant samples (mixtures of DNAs) relative to the pre-
transplant samples (100% recipient DNAs). The % chimerism cal-
culated from DNA dilution series showed linearity with precision
down to at least 0.1% recipient DNA. The calculated % chimerism
was compared to the nominal value for determinations of accuracy
and equivalence of readout between different markers. Inter-assay
variability over three days and between three markers was demon-
strated to meet acceptance criteria.African American African American 2.2%
Asian Asian 0.6%
Hispanic/Latino Hispanic/Latino 0.2%
Caucasian Other 10.9%
Asian Other 8.2%
African American Other 26.6%
Hispanic/Latino Other 52.7%
Multi-Race Other 1.6%
Transplant Type
Single 477 161
Dual 47 8
HLA Match*
<5/6 168 86
$5/6 356 83
Gender*
Male 271 105
Female 242 61
Patient Age
N 524 169
Median (y) 7.8 6.2
Patient Weight
N 524 169
Median (kg) 25.6 21.5
TBI
Yes 264 81
No 231 75
Conditioning Regimen*
Non-Myeloablative 139 71
Myeloablative 365 94
TNC Dose
N 525 169
Median (107/kg) 6.4 6.8
CD34 Dose
N 521 168
Median (105/kg) 2.6 3.0
CFU Dose
N 521 168
Median (105/kg) .39 .39
*Denotes p values <.05.403
SURVIVAL AFTER ALLOGENEIC TRANSPLANT FOR RELAPSED LEUKEMIA
FOLLOWING CYCLOPHOSPHAMIDE, ETOPOSIDE, AND TOTAL BODY RA-
DIATION (TBI) WITH LUNG SHIELDING: INFLUENCE OF cGVHD ON RE-
LAPSE AND LUNG SHIELDING ON PULMONARY COMPLICATIONS
Morris, J.1, Morris, C.L.1, Loredo, L.2 1Loma Linda University Medical
Center, Loma Linda, CA; 2Loma Linda UniversityMedical Center, Loma
Linda, CA
Background: High dose chemotherapy and allogenic stem cell
transplant is used to consolidate relapsed leukemia. GVT is an im-
portant component of curing leukemia in this setting and GVHD
and TBI are important causes of toxicity, most notably late lung
complications. We have employed lung shielding to reduce pulmo-
nary complications in long term survivors of SCT.We report the im-
pact of cGVHD on relapse and the incidence of late lung
complications in these patients.
Method: Thirty-three patients with ALL (24), AML (8), and NHL
(1) in CR2 (28), and . or equal to CR3 (5) received allogeneic
PBSCT. Graft source was unrelated (20), HLA mismatched related
(1), or HLA identical sibling donor (12). All received 1200 cGy TBI,
etoposide 1500mg/m2, and cyclophosphamide 120mg/kg. Unre-
lated or mismatched related stem cell recipients also received ATG
(90mg/kg over 3 days). TBI was delivered in 200cGy fractions twice
daily for 3 days with double lung blocks to reduce lung dose to
300cGy. The chest wall was boosted with electrons to 1200cGy.
GVHD prophylaxis was cyclosporin for matched siblings or tacroli-
mus (all others) and short course methotrexate (10mg/M2 days 1, 3,
6, and 11 except 1 recipient of cord blood who received steroids).
Result:OS andDFSwere 19/33 (actuarial 53%) and 17/33 with me-
dian time from transplant of 41 and 47 months. For patients.1 and
.4 years from transplant, TRMwas 4/28 at 1 year and 4/15 at year 4.
Relapse for patients.1 year from transplant was 7/28 (6/11matched
sibling, 1/16 unrelated, 0/1 mismatched related donor). All relapses
occurred\1 year after transplant except 1 (21 month). The relapse
rate for sibling transplants complicated by cGVHD was 0/4 (all sur-
vived at least 1 year) and was 6/7 for sibling transplants with nocGVHD. The relapse rate for recipients of unrelated PBSC grafts
was 1/12 with 10/12 complicated by cGVHD. Of the 14 patients
with cGVHD it has resolved in 4, requires continued treatment in
5, 2 died of complications from cGVHD, and 1 relapse. There was
one case of idiopathic pneumonitis in a sibling donor transplant oc-
curring within 50 days of transplant. Among 20 patients surviving at
.1 year after transplant there is 1 case of severe restrictive lung dis-
ease due to chest wall contractures from cGVHD.
Conclusion: 1. The best predictor of DFS in this series was presence
of cGVHD. 2. GVHD was the strongest predictor of TRM. 3. Late
pulmonary complications were rare.
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EFFECTIVENESS OF UNRELATED ALLOGENEIC UMBILICAL CORD BLOOD
TRANSPLANTATION FOR ETHNICALLY MATCHED AND MISMATCHED PA-
TIENT POPULATIONS
Wofford, J.1, Sander, J.1, Stocker, A.1, Regan, D.1, Bhatla, D.2 1The St.
Louis Cord Blood Bank, St. Louis, MO; 2St. Louis University School of
Medicine, St. Louis, MO
Allogeneic hematopoietic stem cell transplantation (HSCT) has
become the accepted treatment for many life threatening hemato-
logic diseases. Outcomes are superior when HLA matched related
donors are the stem cell source for allogeneic HSCT. However,
only 15-20% of patients needing a marrow or blood cell transplant
